Health at a Glance 2017
OECD Indicators
![image of Health at a Glance 2017 image of Health at a Glance 2017](https://assets.oecdcode.org/covers/100/g2g800d8.jpg)
This new edition of Health at a Glance presents the most recent comparable data on the health status of populations and health system performance in OECD countries. Where possible, it also reports data for partner countries (Brazil, China, Colombia, Costa Rica, India, Indonesia, Lithuania, Russian Federation and South Africa). The data presented in this publication come from official national statistics, unless otherwise stated.
This edition contains a range of new indicators, particularly on risk factors for health. It also places greater emphasis on time trend analysis. Alongside indicator-by-indicator analysis, this edition offers snapshots and dashboard indicators that summarise the comparative performance of countries, and a special chapter on the main factors driving life expectancy gains.
Generics and biosimilars
All OECD countries view the development of generic markets as a good opportunity to increase efficiency in pharmaceutical spending, but many do not fully exploit the potential of generics (). In 2015, generics accounted for more than three-quarters of the volume of pharmaceuticals sold in the United States, Chile, Germany, New Zealand and the United Kingdom, while they represented less than one-quarter of the market in Luxembourg, Italy, Switzerland and Greece.
Also available in: French
- Click to access:
-
Click to download PDF - 266.25KBPDF